The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection
Abstract
Ideal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8+ T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8+ T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
B lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Approaching the Asymptote? Evolution and Revolution in Immunology
Janeway, C. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,252
Cited by
Membrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
van der Pol, E., Böing, A. N., Harrison, P., Sturk, A., & Nieuwland, R. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005983 · Cited by 1,754
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Self-citationEscudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Self-citationExosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,167
Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses
Bobrie, A., Colombo, M., Raposo, G., & Théry, C. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01225.x · Cited by 1,103
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., & Li, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.1 · Cited by 805
Exosome mediated communication within the tumor microenvironment
Milane, L., Singh, A., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.029 · Cited by 742
Exosomes and other extracellular vesicles in host–pathogen interactions
Schorey, J. S., Cheng, Y., Singh, P. P., & Smith, V. L. (2015) · EMBO reports · doi:10.15252/embr.201439363 · Cited by 727
The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
Peinado, H., Lavotshkin, S., & Lyden, D. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.01.002 · Cited by 654
Dendritic cell-derived exosomes for cancer therapy.
Pitt, J. M., André, F., Amigorena, S., Soria, J.-C., Eggermont, A., Kroemer, G., & Zitvogel, L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81137 · Cited by 636
Self-citationICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming
Segura, E., Nicco, C., Lombard, B., Véron, P., Raposo, G., Batteux, F., Amigorena, S., & Théry, C. (2005) · Blood · doi:10.1182/blood-2005-01-0220 · Cited by 613
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
Exosomes: immune properties and potential clinical implementations
Chaput, N., & Théry, C. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0233-9 · Cited by 560
Self-citationHuman Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Clayton, A., Mitchell, J. P., Court, J., Mason, M. D., & Tabi, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3456 · Cited by 520
André, F., Chaput, N., Schartz, N. E. C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2126 · Cited by 496
Self-citationCell membrane-derived nanomaterials for biomedical applications
Fang, R. H., Jiang, Y., Fang, J. C., & Zhang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.041 · Cited by 468
Induction of heat shock proteins in B-cell exosomes
Clayton, A., Turkes, A., Navabi, H., Mason, M. D., & Tabi, Z. (2005) · Journal of Cell Science · doi:10.1242/jcs.02494 · Cited by 454
Viaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
Self-citationAntigen Presentation by Extracellular Vesicles from Professional Antigen-Presenting Cells
Lindenbergh, M. F. S., & Stoorvogel, W. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055700 · Cited by 373
Zhang, H.-G., & Grizzle, W. E. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.09.027 · Cited by 352
Dendritic Cell-Derived Exosomes for Cancer Immunotherapy: What's Next?
Viaud, S., Théry, C., Ploix, S., Tursz, T., Lapierre, V., Lantz, O., Zitvogel, L., & Chaput, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3276 · Cited by 332
Self-citationTransfer of extracellular vesicles during immune cell‐cell interactions
Gutiérrez‐Vázquez, C., Villarroya‐Beltri, C., Mittelbrunn, M., & Sánchez‐Madrid, F. (2013) · Immunological Reviews · doi:10.1111/imr.12013 · Cited by 323
Role of Exosomes/Microvesicles in the Nervous System and Use in Emerging Therapies
Lai, C. P.-K., & Breakefield, X. O. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00228 · Cited by 315
Exosomes as divine messengers: are they the Hermes of modern molecular oncology?
Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., & Calin, G. A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.130 · Cited by 297
Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer
Pitt, J. M., Charrier, M., Viaud, S., André, F., Besse, B., Chaput, N., & Zitvogel, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400703 · Cited by 296
Self-citationNatural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
Self-citationCD8+ Dendritic Cells Use LFA-1 to Capture MHC-Peptide Complexes from Exosomes In Vivo
Segura, E., Guérin, C., Hogg, N., Amigorena, S., & Théry, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1489 · Cited by 276
Engineering Exosomes for Cancer Therapy
Gilligan, K., & Dwyer, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061122 · Cited by 266
Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells
WATSON, P. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.05.003 · Cited by 265
Montecalvo, A., Shufesky, W. J., Beer Stolz, D., Sullivan, M. G., Wang, Z., Divito, S. J., Papworth, G. D., Watkins, S. C., Robbins, P. D., Larregina, A. T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3081 · Cited by 265
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 258
Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203
Rodrigues, M., Fan, J., Lyon, C., Wan, M., & Hu, Y. (2018) · Theranostics · doi:10.7150/thno.20576 · Cited by 191
“In the so-called “cross-dressing” model, intact MHC-antigen complexes are transferred from inactive to active DC populations [27-30], whereas in the “cross-presentation” mechanism, mature DCs present peptides derived from captured EVs on their own MHC molecules [25, 26].”
BackgroundRomagnoli, G. G., Zelante, B. B., Toniolo, P. A., Migliori, I. K., & Barbuto, J. A. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00692 · Cited by 152
“Also, in a clinical trial, ascites-derived Exo administered with GM-CSF induced CEA-specific-T lymphocytes (17), confirming the potential of Exo to carry and deliver effectively tumor antigens, as observed in various other settings (16, 18).”
BackgroundResultHarnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Shen, A.-R., Jin, X.-X., Tang, T.-T., Ding, Y., Liu, X.-T., Zhong, X., Wu, Y.-D., Han, X.-L., Zhao, G.-Y., Shen, C.-L., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s367494 · Cited by 19
Metadata
- Authors
- Chaput, N., Schartz, N. E. C., André, F., Taïeb, J., Novault, S., Bonnaventure, P., Aubert, N., Bernard, J., Lemonnier, F., Merad, M., Adema, G., Adams, M., Ferrantini, M., Carpentier, A. F., Escudier, B., Tursz, T., Angevin, E., & Zitvogel, L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-02
- Volume
- 172
- Issue
- 4
- Pages
- 2137-2146
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1838162521
- Cited by
- 266
- References
- 50
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.